According to the Zhitong Finance App, Liankang Biotechnology Group (00690) announced its annual results for the year ended December 31, 2023. The Group's revenue reached a record high, reaching approximately HK$484.7 million, an increase of 10.1% year-on-year. Pinupand kinin peptidesThe sales performance was exceptional, with year-on-year increases of 15.0% and 9.54%, respectively. Profit during the year reached approximately HK$70.9 million, a significant year-on-year increase of 84.04%, making it an important milestone for a research biopharmaceutical company.

General and administrative expenses as a percentage of revenue were reduced from 10.7% to 9.8% during the year due to the Group's continued increase in internal controls and cost reduction measures.

Group BogutaiThe new drug marketing application (teriparatide injection) was approved by China's State Drug Administration, marking a major breakthrough in the treatment of orthopedic diseases and providing patients with more choices.

The Group successfully launched Skbrella FN during the year, reaching an important milestone, marking the Group's entry into the premium skincare ingredients market. Currently, Skbrella FN is in the formulation optimization and packaging design stage, and plans to officially launch its own fibronectin medical beauty brand in 2024.

During the year, the Group established the “Green Peptide Innovative Drug and Advanced Technology Research and Development Center” in Beijing. This cutting-edge facility incorporates the latest advances in bioinformatics technology, genetic engineering, and oral formulation technology, marking a transformative era for the biosynthetic peptide drug industry.